Clearside Biomedical (CLSD) Stock Rating Lowered by ValuEngine

ValuEngine downgraded shares of Clearside Biomedical (NASDAQ:CLSD) from a buy rating to a hold rating in a report published on Friday.

Several other research firms also recently commented on CLSD. BidaskClub downgraded Clearside Biomedical from a strong-buy rating to a buy rating in a report on Friday, June 8th. Needham & Company LLC boosted their target price on Clearside Biomedical from $18.00 to $22.00 and gave the stock a buy rating in a report on Tuesday, March 6th. Wedbush reissued an outperform rating and issued a $29.00 target price on shares of Clearside Biomedical in a report on Tuesday, March 20th. JPMorgan Chase & Co. reissued an overweight rating and issued a $18.00 target price (up from $15.00) on shares of Clearside Biomedical in a report on Tuesday, March 6th. Finally, JMP Securities set a $25.00 target price on Clearside Biomedical and gave the stock a buy rating in a report on Saturday, June 9th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus target price of $20.80.

Clearside Biomedical opened at $10.09 on Friday, according to Marketbeat Ratings. The company has a debt-to-equity ratio of 0.05, a quick ratio of 7.46 and a current ratio of 7.46. Clearside Biomedical has a twelve month low of $5.30 and a twelve month high of $15.33. The company has a market cap of $330.97 million, a P/E ratio of -4.33 and a beta of -7.22.

Clearside Biomedical (NASDAQ:CLSD) last released its quarterly earnings results on Wednesday, May 9th. The company reported ($0.62) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.57) by ($0.05). Clearside Biomedical had a negative net margin of 17,094.20% and a negative return on equity of 131.37%. research analysts predict that Clearside Biomedical will post -2.39 EPS for the current fiscal year.

In other Clearside Biomedical news, insider Daniel H. White purchased 11,000 shares of the firm’s stock in a transaction dated Monday, June 4th. The stock was purchased at an average price of $9.07 per share, for a total transaction of $99,770.00. Following the completion of the purchase, the insider now directly owns 472,335 shares of the company’s stock, valued at $4,284,078.45. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Clay Thorp sold 161,139 shares of the business’s stock in a transaction on Friday, May 18th. The stock was sold at an average price of $13.08, for a total value of $2,107,698.12. The disclosure for this sale can be found here. Insiders own 15.40% of the company’s stock.

Several hedge funds have recently bought and sold shares of the company. Dynamic Technology Lab Private Ltd purchased a new position in shares of Clearside Biomedical in the first quarter worth $152,000. EAM Global Investors LLC purchased a new position in shares of Clearside Biomedical in the first quarter worth $903,000. Millennium Management LLC raised its stake in shares of Clearside Biomedical by 5,396.6% in the first quarter. Millennium Management LLC now owns 1,397,732 shares of the company’s stock worth $14,998,000 after purchasing an additional 1,372,303 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new position in shares of Clearside Biomedical in the first quarter worth $132,000. Finally, Sofinnova Ventures Inc purchased a new position in shares of Clearside Biomedical in the first quarter worth $380,000. Hedge funds and other institutional investors own 61.48% of the company’s stock.

About Clearside Biomedical

Clearside Biomedical, Inc, a late-stage clinical biopharmaceutical company, develops pharmacological therapies to treat blinding diseases of the eye. It is developing suprachoroidal injection of CLS-TA, a proprietary preservative-free formulation of the corticosteroid triamcinolone acetonide, which is in Phase III clinical trial for the treatment of macular edema associated with non-infectious uveitis; suprachoroidal injection of CLS-TA and a concomitant intravitreal injection of Eylea, an inhibitor of vascular endothelial growth factor that is in Phase III clinical trial to treat macular edema associated with retinal vein occlusion; and suprachoroidal injection of CLS-TA alone or together with intravitreal injection of Eylea that is in phase II clinical trial for diabetic macular edema.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Clearside Biomedical (NASDAQ:CLSD)

Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply